Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)

NCT00000810 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

120

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Delavirdine mesylate
DRUG: Zidovudine
DRUG: Didanosine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)